HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts

This article was originally published in The Tan Sheet

Executive Summary

FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.

You may also be interested in...



New Products In Brief

Pfizer launches new line, extends Centrum

Advisory Committee On NRT Indications Appears Likely Following Workshop

Speakers at a workshop on nicotine-replacement therapy point abroad for guidance on expanding indications for smoking-cessation products as an FDA official says the agency likely will put the question before an advisory committee.

FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds

Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication

Related Content

Topics

UsernamePublicRestriction

Register

RS134174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel